SCHEMBL4775306

SCHEMBL4775306

CCN1CCN(c2nc(-c3ccc(CC(C)(C)C(=O)OC)cc3)cc3ccccc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
TP53 P04637 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
PKN2 Q16513 1/20 0.40
USP2 O75604 2/20 0.39
MAPK1 P28482 2/20 0.39
ACP1 P24666 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 1/20 0.38
BCHE P06276 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772851 0.86 SMN1; SMN2 (0.43) ALDH1A1HPGDROCK2ROCK1PKN2
SCHEMBL4775424 0.86 SMN1; SMN2 (0.39) KDM4EALDH1A1TP53HPGDHSD17B10
Oxalic Acid SCHEMBL4775416 0.86 SMN1; SMN2 (0.42) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL6288784 0.84 SMN1; SMN2 (0.38) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL4775422 0.84 RXFP1 (0.37) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL4766165 0.84 SMN1; SMN2 (0.41) ALDH1A1HPGDROCK2ROCK1PKN2
Oxalic Acid SCHEMBL6288783 0.83 SMN1; SMN2 (0.40) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL4763897 0.81 USP2 (0.41) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL4763754 0.81 SMN1; SMN2 (0.43) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL4766408 0.81 SMN1; SMN2 (0.46) ALDH1A1HPGDROCK2ROCK1PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 KDM4E 1050/4885ALDH1A1 2989/4885TP53 2427/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 KDM4E 1058/4885ALDH1A1 1071/4885TP53 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.